Literature DB >> 31838768

Epidemiology and outcome of idiopathic generalized epilepsy in adults.

J Gesche1,2, J Christensen3, H Hjalgrim4,5, G Rubboli4,6, C P Beier1,2,7.   

Abstract

BACKGROUND AND
PURPOSE: Drug-resistant idiopathic generalized epilepsy (IGE) remains challenging despite a favourable overall prognosis of IGE, and little is known about basic epidemiology and long-term outcome of drug-resistant IGE. The aim of the study was to describe the incidence, prevalence and outcome of IGE in an unbiased, population-based cohort.
METHODS: In 2014-2018, all patients (≥17 years) with IGE inhabiting the island of Funen (496 000 inhabitants) were recruited. The socioeconomic and clinical information available for 406 individuals was assessed. Median follow-up was 15 years.
RESULTS: The average IGE incidence (2008-2017) was 2.9/100 000 inhabitants/year. The point prevalence of identifiable IGE patients was 1.0/1000 adults (juvenile myoclonic epilepsy 0.4/1000; absence epilepsy 0.3/1000, epilepsy with generalized tonic-clonic seizures alone 0.3/1000); 92.1% of the patients were diagnosed before 25 years of age. When correcting for unequal age distribution in the cohort, 1102 people on the island of Funen fulfilled the diagnostic criteria for IGE at the age of 25 (estimated prevalence 2.7/1000 adults). In the year before data closure, 121 patients reported seizures. Fifty patients met the definition of drug-resistant IGE (12.1% of the cohort, 4.5% of the estimated 1102 IGE patients). The average seizure burden of all patients with drug-resistant IGE was 2.2 generalized tonic-clonic seizures per year; only 14 patients suffered more than two generalized tonic-clonic seizures per year. Drug-resistant IGE was associated with an increased risk of requiring treatment for affective disorders and a reduced probability of working full time.
CONCLUSION: Idiopathic generalized epilepsy was associated with a low risk of persistent drug-resistant seizures requiring specialist medical attention. Drug resistance was associated with a negative socioeconomic outcome.
© 2019 European Academy of Neurology.

Entities:  

Keywords:  burden of disease; drug resistance; epidemiology; genetic generalized epilepsy; idiopathic; incidence; outcome; prevalence

Mesh:

Substances:

Year:  2020        PMID: 31838768     DOI: 10.1111/ene.14142

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  Different Prognostic Patterns in Epilepsies and Considerations About the Denotations of Atypical Patterns.

Authors:  Arife Çimen Atalar; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2022-01-31       Impact factor: 1.339

Review 2.  Genetic generalized epilepsies in adults - challenging assumptions and dogmas.

Authors:  Bernd J Vorderwülbecke; Britta Wandschneider; Yvonne Weber; Martin Holtkamp
Journal:  Nat Rev Neurol       Date:  2021-11-26       Impact factor: 42.937

3.  Centromedian Nucleus of the Thalamus Deep Brain Stimulation for Genetic Generalized Epilepsy: A Case Report and Review of Literature.

Authors:  Shruti Agashe; David Burkholder; Keith Starnes; Jamie J Van Gompel; Brian N Lundstrom; Gregory A Worrell; Nicholas M Gregg
Journal:  Front Hum Neurosci       Date:  2022-05-20       Impact factor: 3.473

4.  Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalised epilepsy: initial case series.

Authors:  Nathaniel D Sisterson; Vasileios Kokkinos; Alexandra Urban; Ningfei Li; R Mark Richardson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-02-25       Impact factor: 13.654

5.  Amplitude of Low-Frequency Fluctuation With Different Clinical Outcomes in Patients With Generalized Tonic-Clonic Seizures.

Authors:  Meidan Zu; Lulan Fu; Mingwei Hu; Xiaoyan Cao; Long Wang; Juan Zhang; Ziru Deng; Bensheng Qiu; Yu Wang
Journal:  Front Psychiatry       Date:  2022-04-01       Impact factor: 5.435

6.  Responsive Neurostimulation of the Thalamus for the Treatment of Refractory Epilepsy.

Authors:  Jorge A Roa; Marina Abramova; Madeline Fields; Maite La Vega-Talbott; Jiyeoun Yoo; Lara Marcuse; Steven Wolf; Patricia McGoldrick; Saadi Ghatan; Fedor Panov
Journal:  Front Hum Neurosci       Date:  2022-07-15       Impact factor: 3.473

7.  Risk of hospitalization and death for COVID-19 in persons with epilepsy over a 20-month period: The EpiLink Bologna cohort, Italy.

Authors:  Lorenzo Muccioli; Corrado Zenesini; Lisa Taruffi; Laura Licchetta; Barbara Mostacci; Lidia Di Vito; Elena Pasini; Lilia Volpi; Patrizia Riguzzi; Lorenzo Ferri; Flavia Baccari; Francesco Nonino; Roberto Michelucci; Paolo Tinuper; Luca Vignatelli; Francesca Bisulli
Journal:  Epilepsia       Date:  2022-07-17       Impact factor: 6.740

8.  Application of Machine Learning Methods for Epilepsy Risk Ranking in Patients with Hematopoietic Malignancies Using.

Authors:  Iaroslav Skiba; Georgy Kopanitsa; Oleg Metsker; Stanislav Yanishevskiy; Alexey Polushin
Journal:  J Pers Med       Date:  2022-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.